# US 2019/0376027 A1 · Composition for collecting and preserving placental stem cells and methods of using the composition

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0376027 A1
- Document ID: US20190376027A1
- Status: Published application
- Kind: A1
- Application number: 16/548,720
- Filed: 2019-08-22
- Published: 2019-12-12
- Earliest claimed: 2005-12-29
- Assignees: Celularity Inc.
- Applicants: Celularity, Inc.
- Inventors: James W. Edinger; Mohammad Heidaran; Wolfgang Hofgartner
- Web page: https://patentgrep.com/patent/US20190376027A1

## CPC

- C12N 5/0605: {Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly}
- C12N 2501/48: Regulators of apoptosis
- C12N 2501/999: Small molecules not provided for elsewhere
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides improved compositions and methods for the collection of stem cells from an organ, e.g., placenta. The invention provides a stem cell collection composition comprising an apoptosis inhibitor and, optionally, an enzyme such as a protease or mucolytic enzyme, vasodilator, necrosis inhibitor, oxygen-carrying perfluorocarbon, or an organ preserving compound. The invention provides methods of using the stem cell collection composition to collect stem cells and to preserve populations of stem cells.

## Claims

### Claim 1

A composition comprising, in a physiologically-acceptable solution, an inhibitor of apoptosis and a protease,
wherein said composition, when contacted with population of stem cells, reduces or prevents apoptosis in said population of stem cells as compared to a population of stem cells not contacted with the composition, and wherein said composition is not a naturally-occurring composition.

### Claim 2 (depends on 1)

The composition of claim 1, wherein said inhibitor of apoptosis is a caspase inhibitor.

### Claim 3 (depends on 1)

The composition of claim 1, wherein said inhibitor of apoptosis is a JNK inhibitor.

### Claim 4 (depends on 1)

The composition of claim 1, wherein said JNK inhibitor does not modulate differentiation or proliferation of said stem cells.

### Claim 5 (depends on 1)

The composition of claim 1, wherein said protease is present in an amount sufficient to detectably dissociate the cells of a tissue from which said stem cells may be derived.

### Claim 6 (depends on 1)

The composition of claim 1, additionally comprising an inhibitor of necrosis.

### Claim 7 (depends on 6)

The composition of claim 6, wherein said inhibitor of necrosis is 2-(1H-Indol-3-yl)-3-pentylamino-maleimide.

### Claim 8 (depends on 1)

The composition of claim 1, additionally comprising an oxygen-carrying perfluorocarbon.

### Claim 9 (depends on 1)

The composition of claim 1 wherein said physiologically-acceptable solution is a saline solution or culture medium.

### Claim 10 (depends on 9)

The composition of claim 9 wherein said saline solution is 0.9% NaCl solution or phosphate buffered saline.

### Claim 11 (depends on 1)

The composition of claim 1, wherein said protease is a matrix metalloprotease or a neutral protease.

### Claim 12 (depends on 11)

The composition of claim 11, wherein said matrix metalloprotease is collagenase.

### Claim 13 (depends on 11)

The composition of claim 11, wherein said neutral protease is thermolysin or dispase.

### Claim 14 (depends on 11)

The composition of claim 11 additionally comprising a mucolytic enzyme.

### Claim 15 (depends on 14)

The composition of claim 14, wherein said mucolytic enzyme is hyaluronidase.

### Claim 16 (depends on 1)

The composition of claim 1, additionally comprising hydroxyethyl starch, lactobionic acid and raffinose.

### Claim 17 (depends on 1)

The composition of claim 1, additionally comprising UW solution.

### Claim 18 (depends on 1)

The composition of claim 1, wherein said JNK inhibitor is an indazole.

### Claim 19 (depends on 1)

The composition of claim 1, wherein said JNK inhibitor has the structure
wherein:
A is a direct bond, —(CH2)a—, —(CH2)bCH═CH(CH2)c—, or —(CH2)bC≡C(CH2)c—;
R1 is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from R3;
R2 is —R3, —R4, —(CH2)bC(═O)R5, —(CH2)bC(═O)OR5, —(CH2)bC(═O)NR5R6,
—(CH2)bC(═O)NR5(CH2)cC(═O)R6, —(CH2)bNR5C(═O)R6,
—(CH2)bNR5C(═O)NR6R7, —(CH2)bNR5R6, —(CH2)bOR5,
—(CH2)bSOdR5 or —(CH2)bSO2NR5R6;
a is 1, 2, 3, 4, 5 or 6;
b and c are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;
d is at each occurrence 0, 1 or 2;
R3 is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl, —C(═O)OR8, —OC(═O)R8, —C(═O)NR8R9, —C(═O)NR8OR9, —SO2NR8R9, —NR8SO2R9, —CN, —NO2, —NR8R9, —NR8C(═O)R9, —NR8C(═O)(CH2)bOR9, —NR8C(═O)(CH2)bR9, —O(CH2)bNR8R9, or heterocycle fused to phenyl;
R4 is alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, each being optionally substituted with one to four substituents independently selected from R3, or R4 is halogen or hydroxy;
R5, R6 and R7 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocycloalkyl, wherein each of R5, R6 and R7 are optionally substituted with one to four substituents independently selected from R3; and
R8 and R9 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocycloalkyl, or R8 and R9 taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of R8, R9, and R8 and R9 taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from R3;
or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof.

### Claim 20 (depends on 1)

The composition of claim 1, wherein said JNK inhibitor has the structure
wherein:
R1 is aryl or heteroaryl optionally substituted with one to four substituents independently selected from R7;
R2 is hydrogen;
R3 is hydrogen or lower alkyl;
R4 represents one to four optional substituents, wherein each substituent is the same or different and independently selected from halogen, hydroxy, lower alkyl and lower alkoxy;
R5 and R6 are the same or different and independently —R8, —(CH2)aC(═O)R9, —(CH2)aC(═O)OR9, —(CH2)aC(═O)NR9R10, —(CH2)aC(═O)NR9(CH2)bC(═O)R10, —(CH2)aNR9C(═O)R10, (CH2)aNR11C(═O)NR9R10, —(CH2)aNR9R10, —(CH2)aOR9, —(CH2)aSOcR9 or —(CH2)aSO2NR9R10;
or R5 and R6 taken together with the nitrogen atom to which they are attached to form a heterocycle or substituted heterocycle;
R7 is at each occurrence independently halogen, hydroxy, cyano, nitro, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, arylalkyl, heterocycle, substituted heterocycle, heterocycloalkyl, —C(═O)OR8, —OC(═O)R8, —C(═O)NR8R9, —C(═O)NR8OR9, —SOcR8, —SOcNR8R9, —NR8SOcR9, —NR8R9, —NR8C(═O)R9, —NR8C(═O)(CH2)bOR9, —NR8C(═O)(CH2)bR9, —O(CH2)bNR8R9, or heterocycle fused to phenyl;
R8, R9, R10 and R11 are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, heterocycloalkyl;
or R8 and R9 taken together with the atom or atoms to which they are attached to form a heterocycle;
a and b are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4; and
c is at each occurrence 0, 1 or 2;
or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof.

### Claim 21 (depends on 1)

The composition of claim 1, wherein said JNK inhibitor has the structure
wherein R0 is —O—, —S—, —S(O)—, —S(O)2—, NH or —CH2—;
the compound of structure (III) being: (i) unsubstituted, (ii) monosubstituted and having a first substituent, or (iii) disubstituted and having a first substituent and a second substituent;
the first or second substituent, when present, is at the 3, 4, 5, 7, 8, 9, or 10 position, wherein the first and second substituent, when present, are independently alkyl, hydroxy, halogen, nitro, trifluoromethyl, sulfonyl, carboxyl, alkoxycarbonyl, alkoxy, aryl, aryloxy, arylalkyloxy, arylalkyl, cycloalkylalkyloxy, cycloalkyloxy, alkoxyalkyl, alkoxyalkoxy, aminoalkoxy, mono-alkylaminoalkoxy, di-alkylaminoalkoxy, or a group represented by structure (a), (b), (c), (d), (e), or (f):
wherein R3 and R4 are taken together and represent alkylidene or a heteroatom-containing cyclic alkylidene or R3 and R4 are independently hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, aryloxyalkyl, alkoxyalkyl, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl; and
R5 is hydrogen, alkyl, cycloalkyl, aryl, arylalkyl, cycloalkylalkyl, alkoxy, alkoxyalkyl, alkoxycarbonylalkyl, amino, mono-alkylamino, di-alkylamino, arylamino, arylalkylamino, cycloalkylamino, cycloalkylalkylamino, aminoalkyl, mono-alkylaminoalkyl, or di-alkylaminoalkyl;
or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof

### Claim 22 (depends on 1)

The composition of claim 1, additionally comprising an immunomodulatory compound.

### Claim 23 (depends on 22)

The composition of claim 22, wherein said immunomodulatory compound is 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione; 3-(4′aminoisolindoline-1′-onw)-1-piperidine-2,6-dione; 4-(Amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione; or α-(3-aminophthalimido) glutarimide.

### Claim 24 (depends on 22)

The composition of claim 22, wherein said immunomodulatory compound is a compound having the structure
wherein one of X and Y is C═O, the other of X and Y is C═O or CH2, and R2 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof

### Claim 25 (depends on 22)

The composition of claim 22, wherein said immunomodulatory compound is a compound having the structure
wherein one of X and Y is C═O and the other is CH2 or C═O;
R1 is H, (C1-C8)alkyl, (C3-C7)cycloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, benzyl, aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, (C0-C4)alkyl-(C2-C5)heteroaryl, C(O)R3, C(S)R3, C(O)OR4, (C1-C8)alkyl-N(R6)2, (C1-C8)alkyl-OR5, (C1-C8)alkyl-C(O)OR5, C(O)NHR3, C(S)NHR3, C(O)NR3R3′, C(S)NR3R3′ or (C1-C8)alkyl-O(CO)R5;
R2 is H, F, benzyl, (C1-C8)alkyl, (C2-C8)alkenyl, or (C2-C8)alkynyl;
R3 and R3′ are independently (C1-C8)alkyl, (C3-C7)cycloalkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, benzyl, aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, (C0-C4)alkyl-(C2-C5)heteroaryl, (C0-C8)alkyl-N(R6)2, (C1-C8)alkyl-OR5, (C1-C8)alkyl-C(O)OR5, (C1-C8)alkyl-O(CO)R5, or C(O)OR5;
R4 is (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, (C1-C4)alkyl-OR5, benzyl, aryl, (C0-C4)alkyl-(C1-C6)heterocycloalkyl, or (C0-C4)alkyl-(C2-C5)heteroaryl;
R5 is (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, benzyl, aryl, or (C2-C5)heteroaryl;
each occurrence of R6 is independently H, (C1-C8)alkyl, (C2-C8)alkenyl, (C2-C8)alkynyl, benzyl, aryl, (C2-C5)heteroaryl, or (C0-C8)alkyl-C(O)O—R5 or the R6 groups can join to form a heterocycloalkyl group;
n is 0 or 1; and
* represents a chiral-carbon center;
or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof

### Claim 26 (depends on 22)

The composition of claim 22, wherein said immunomodulatory compound is a compound having the structure
wherein:
one of X and Y is C═O and the other is CH2 or C═O;
R is H or CH2OCOR′;
(i) each of R1, R2, R3, or R4, independently of the others, is halo, alkyl of 1 to 4 carbon atoms, or alkoxy of 1 to 4 carbon atoms or (ii) one of R1, R2, R3, or R4 is nitro or —NHR5 and the remaining of R1, R2, R3, or R4 are hydrogen;
R5 is hydrogen or alkyl of 1 to 8 carbons
R6 hydrogen, alkyl of 1 to 8 carbon atoms, benzo, chloro, or fluoro;
R′ is R7—CHR10—N(R8R9);
R7 is m-phenylene or p-phenylene or —(CnH2n)— in which n has a value of 0 to 4;
each of R8 and R9 taken independently of the other is hydrogen or alkyl of 1 to 8 carbon atoms, or R8 and R9 taken together are tetramethylene, pentamethylene, hexamethylene, or —CH2CH2X1CH2CH2— in which X1 is —O—, —S—, or —NH—;
R10 is hydrogen, alkyl of to 8 carbon atoms, or phenyl; and
* represents a chiral-carbon center;
or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, enantiomer, diastereomer, racemate, or mixture of stereoisomers thereof.

### Claim 27 (depends on 1)

The composition of claim 1, wherein said perfusion solution additionally comprises a vasodilator.

### Claim 28 (depends on 27)

The composition of claim 27, wherein said vasodilator is an antihypertensive drug.

### Claim 29 (depends on 27)

The composition of claim 27, wherein said vasodilator activates guanylyl cyclase, ADP-ribosyl transferase or cyclooxygenase, or inhibits lipoxygenase.

### Claim 30 (depends on 27)

The composition of claim 27, wherein said vasodilator is atrial natriuretic peptide (ANP), adrenocorticotropin, corticotropin-releasing hormone, sodium nitroprusside, hydralazine, adenosine triphosphate, adenosine, indomethacin or magnesium sulfate.

### Claim 31 (depends on 30)

The composition of claim 30, wherein said hydralazine is present in a concentration of from about 0.1 mM to about 10 mM.

### Claim 32 (depends on 30)

The composition of claim 30, wherein said adenosine is present at a concentration of about 0.001 mM to about 10.0 mM.

### Claim 33 (depends on 30)

The composition of claim 30, wherein said adenosine triphosphate is present at a concentration of about 0.1 mM to about 1000 mM.

### Claim 34 (depends on 30)

The composition of claim 30, wherein said indomethacin is present at a concentration of about 1 mg/kg to about 20 mg/kg, wherein “kg” is the weight of the placenta.

### Claim 35 (depends on 30)

The composition of claim 30, wherein said magnesium sulfate is present at a concentration of about 0.1 mM to about 20 mM.
